Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Current Deferred Revenue (2021)

Historic Current Deferred Revenue for Pharmaceuticals (CASI) over the last 1 years, with Q4 2021 value amounting to $2.8 million.

  • Pharmaceuticals' Current Deferred Revenue changed N/A to $2.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $2.8 million, marking a year-over-year change of. This contributed to the annual value of $2.8 million for FY2021, which is N/A changed from last year.
  • As of Q4 2021, Pharmaceuticals' Current Deferred Revenue stood at $2.8 million.
  • Over the past 5 years, Pharmaceuticals' Current Deferred Revenue peaked at $2.8 million during Q4 2021, and registered a low of $2.8 million during Q4 2021.